Entrectinib-d8, CAS 2251773-94-9

Product Description: Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC50 values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice[1][2][3][4].

Formula: C31H26D8F2N6O2

References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Miao Y, et al. Entrectinib ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β1 signaling pathway. Int Immunopharmacol. 2022 Dec;113(Pt B):109427. /[3]Ardini E, et al. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016 Apr;15(4):628-39./[4]Iyer R, et al. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett. 2016 Mar 28;372(2):179-86.

CAS Number: 2251773-94-9

Molecular Weight: 568.69

Compound Purity: 99.82

Research Area: cancer

Solubility: DMSO : 100 mg/mL (ultrasonic)

Target: Anaplastic lymphoma kinase (ALK);Autophagy;Isotope-Labeled Compounds;ROS Kinase;Trk Receptor

• Artikelnummer: MEXHY-12678S1-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-12678S1-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK